Test Price
2,800 AED✅ Home Collection Available
ZBTB16 Gene NGS Test (PLZF/RARA) for Acute Promyelocytic Leukemia in Dubai | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
- Diagnostic Precision: 99.9% diagnostic sensitivity via ISO‑certified Next‑Generation Sequencing workflow.
- Premium Logistics: VIP mobile phlebotomy with temperature‑controlled cold‑chain home collection available daily from 8 AM to 11 PM across all UAE emirates.
- Clinical Guidance: Post‑test telephone consultation with a consultant medical geneticist to interpret results in the context of your complete clinical profile.
- Insurance Verification: Direct billing and coverage confirmation via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This Next‑Generation Sequencing (NGS) test examines the ZBTB16 gene for pathogenic variants and detects the PLZF‑RARA fusion transcript — the defining molecular abnormality in a subtype of acute promyelocytic leukemia (APL) that exhibits primary resistance to standard all‑trans retinoic acid (ATRA) therapy. The assay delivers definitive molecular diagnosis, guides precision treatment selection, and enables sensitive minimal residual disease monitoring with unmatched analytical accuracy.
| Feature | Our NGS Test | Closest Alternative (PCR‑Only) |
|---|---|---|
| Precision | 99.9% diagnostic sensitivity; captures all known ZBTB16 variants and fusion breakpoints | Limited to PML‑RARA; misses PLZF‑RARA fusions entirely |
| Method | Next‑Generation Sequencing (full gene sequencing + fusion transcript analysis) | Targeted PCR only for common fusion transcripts |
| Turnaround | 3–4 weeks (comprehensive genomic data) | Faster but incomplete; may require reflex NGS testing |
| Clinical Utility | Identifies ATRA‑resistant APL variant; enables personalized therapy selection | Cannot distinguish PLZF‑RARA variant; risk of clinical misclassification |
Physician Insight & Safety Protocols
“As a consultant medical geneticist, I recognise that the period while awaiting genetic test results can be clinically and emotionally challenging. This analysis is essential to confirm whether your acute promyelocytic leukemia carries the PLZF‑RARA fusion, which fundamentally alters therapeutic decision‑making. All results must be interpreted alongside your full clinical presentation, blood counts, and bone marrow morphology — never in isolation.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA Registration ID: 9294403
Medication Advisory
Do not discontinue, alter, or adjust any prescribed medication — including all‑trans retinoic acid (ATRA), arsenic trioxide, or chemotherapy — without direct consultation with your treating haematologist or oncologist. Test results are designed to inform, not replace, clinical management decisions made by your healthcare team.
Exclusion Criteria & Emergency Red Flags
- Exclusion: No absolute contraindication to standard peripheral blood draw. If you are currently taking anticoagulant therapy, please inform the phlebotomist prior to collection.
- Seek immediate emergency care if you experience: sudden unexplained bleeding or bruising, severe headache, visual disturbances, confusion, or shortness of breath — these may indicate leukostasis, intracranial haemorrhage, or differentiation syndrome requiring urgent medical intervention.
Patient FAQ & Clinical Guidance
1. What is the ZBTB16 PLZF/RARA test used for?
This test identifies the PLZF‑RARA fusion gene, which defines a rare but clinically distinct subtype of acute promyelocytic leukemia (APL) that is inherently resistant to standard ATRA therapy. Detection of this fusion directly influences treatment selection, prognosis assessment, and monitoring of residual disease after therapy.
2. How does NGS improve diagnostic accuracy compared to standard PCR methods?
NGS comprehensively sequences the entire ZBTB16 gene and simultaneously detects all known fusion breakpoints in a single assay. Standard PCR methods are typically designed only for common fusions such as PML‑RARA and will systematically miss the PLZF‑RARA rearrangement, potentially leading to incorrect classification and inappropriate therapy.
3. Is home blood collection available across all seven UAE emirates?
Yes. Our ISO‑certified phlebotomists provide VIP mobile phlebotomy and temperature‑controlled cold‑chain home collection services across all emirates — including Dubai, Abu Dhabi, Sharjah, Ajman, Umm Al Quwain, Ras Al Khaimah, and Fujairah — from 8 AM to 11 PM daily. All samples are transported under strict chain‑of‑custody protocols to our Dubai Healthcare City laboratory.
4. How long does it take to receive my NGS results?
The standard turnaround time is 3 to 4 weeks from sample receipt. This duration reflects the comprehensive nature of full gene sequencing, bioinformatic analysis, and clinical variant interpretation required to deliver an accurate and actionable report.
5. Will my health insurance cover the cost of this genetic test?
Coverage depends on your individual insurance policy and provider. Our billing team can verify your coverage and assist with direct insurance billing. Please contact us via WhatsApp at +971 54 548 8731 for a personalised verification before scheduling your collection.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance: DNA Labs UAE operates under DHA Facility License Number 1143 and adheres strictly to the legal framework established by Federal Decree‑Law No. 45 of 2021 on the Protection of Personal Data (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All clinical testing and patient consent procedures comply with Federal Decree‑Law No. 4 of 2016 on Medical Liability. Our laboratory holds ISO 9001:2015 certification (Cert: INT/EGQ/2509DA/3139).
Direct billing and insurance support: WhatsApp +971 54 548 8731
Clinical & Logistical Metadata
| Test Name | ZBTB16 Gene NGS Test (PLZF/RARA Fusion) for Acute Promyelocytic Leukemia |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 weeks from sample receipt |
| Sample Type / Matrix | Peripheral Whole Blood (3–5 mL in EDTA tube) — VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection Available Daily from 8 AM to 11 PM |
| Methodology Used | Next‑Generation Sequencing (NGS) — Full gene sequencing plus fusion transcript analysis |
| ICD-10-CM Code | C92.4 (Acute promyelocytic leukemia) |
| LOINC Code | 76512-5 (PLZF/RARA fusion transcript [Presence] in Blood or Bone marrow by NGS) |
| DHA Facility License & Laboratory Address | DHA Facility License Number: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE — DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians